ESMO Media Releases

One in two patients with metastatic melanoma is alive with combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019.

Men with prostate cancer can be spared radiotherapy after surgery, according to late breaking results of the RADICALS-RT trial presented at the ESMO Congress 2019 in Barcelona, Spain. 

New data have shown a trend towards clinically meaningful improvements in survival and response rates and a favourable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC).

Many new anti-cancer medicines add little value for patients compared to standard treatment and are rarely worth the extra cost, according to results of two studies investigating links between clinical benefit and pricing in Europe and the USA, reported at the ESMO Congress 2019.

An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research published in the leading cancer journal Annals of Oncology today.

The European Society for Medical Oncology (ESMO), the leading organisation for medical oncology, has revealed the 2019 winners of its annual awards.

Prof. Eric Van Cutsem has been selected for the 2019 ESMO Award, which will be presented to him at this year’s ESMO Congress taking place in Barcelona, 27 September - 1 October.

Prof. Angelo Di Leo will be presented with the ESMO Lifetime Achievement Award during the Opening Ceremony of the ESMO Congress taking place in Barcelona, 27 September - 1 October.

This year’s ESMO Women for Oncology Award goes to Cristiana Sessa, who will receive the distinction at the ESMO Congress 2019 taking place in Barcelona from 27 September to 1 October

Prof. Charles Swanton is the winner of this year’s ESMO Translational Research Award, which will be presented to him at the upcoming ESMO Congress 2019 in Barcelona.

Participants from all over the world are expected in Barcelona, Spain, between 24 September and 1 October to attend the leading international oncology event in Europe, the ESMO Congress 2019.

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC)